The Evolution of Oral Anticoagulant Therapy

Primary Care - Clinics in Office Practice

Volumn 40, Issue 1, 2013, Pages 109-134

  Dittus, Christopher ^a   Ansell, Jack ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

Anticoagulation; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; DALTEPARIN; EDOXABAN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; EMBOLISM PREVENTION; ENDOTHELIAL DYSFUNCTION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; DRUG MONITORING; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNATIONAL NORMALIZED RATIO; MEDICATION ADHERENCE; ORTHOPEDIC PROCEDURES; PARTIAL THROMBOPLASTIN TIME; POLYSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84873595198     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2012.11.011     Document Type: Review

References (40)

1. Di Nisio M., Middeldorp S., Buller H.R. Direct thrombin inhibitors. N Engl J Med 2005, 353:1028-1040.
2. Soff G.A. A new generation of oral direct anticoagulants. Arterioscler Thromb Vasc Biol 2012, 32(3):569-574.
3. Blommel M.L., Blommel A.L. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm 2011, 68(16):1506-1519.
4. Ageno W., Gallus A.S., Wittkowsky A., et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e44S-e88S.
5. Stangier J., Rathgen K., Stahle H., et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharm 2010, 49(4):259-268.
6. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 2012, 26(1):27-32.
7. Asmis L.M., Alberio L., Angelillo-Scherrer A., et al. Rivaroxaban: quantification by anti-Xa assay and influence on coagulation tests, a study in 9 Swiss laboratories. Thromb Res 2012, 129(4):492-498.
8. Prom R., Spinler S.A. The role of apixaban for venous and arterial thromboembolic disease. Ann Pharmacother 2011, 45:1262-1283.
9. Guigliano R.P., Partida R.A. Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future Cardiol 2011, 7(4):459-470.
10. Eriksson B.I., Dahl O.E., Rosencher N., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5(11):2178-2185.
11. Eriksson B.I., Dahl O.E., Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007, 370(9591):949-956.
12. Ginsberg J.S., Davidson B.L., Comp P.C., et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thrombosis after knee arthroplasty surgery. J Arthroplasty 2009, 24(1):1-9.
13. Eriksson B.I., Dahl O.E., Huo M.H., et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): a randomised, double-blind, non-inferiority trial. Thromb Haemost 2011, 105:721-729.
14. Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
15. Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-39.
16. Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
17. Turpie A.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373(9676):1673-1680.
18. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
19. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010, 375:807-815.
20. Lassen M.R., Gallus A., Raskob G.E., et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363:2487-2498.
21. Raskob G., Cohen A.T., Eriksson B.I., et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomized double-blind dose-response study. Thromb Haemost 2010, 104(3):642-649.
22. Cohen A, Spiro T, Buller H, et al. Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. In: American College of Cardiology 60th Annual Scientific Session and Expo. New Orleans, April 5, 2011.
23. Goldhaber S.Z., Leizorovicz A., Kakkar A.K., et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011, 365(23):2167-2177.
24. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
25. Schulman S, Kakkar AK, Schellong SM, et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). American Society of Hematology 2011 Annual Meeting (Abstract 205). San Diego, December 12, 2011.
26. Schulman S., Baanstra D., Eriksson S., et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. Abstract O-MO-037. Abstracts of the XXIII Congress of the International Society on Thrombosis and Haemostasis with the 57th Annual SSC (Scientific and Standardization Committee) Meeting. July 23-28 2011. Kyoto, Japan. J Thromb Haemost 2011, 9(2):22.
27. Einstein Investigators Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
28. EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
29. Romualdi E., Donadini M.P., Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther 2011, 9(7):841-844.
30. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
31. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
32. Granger C.B., Alexander J.H., McMurray J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
33. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
34. Weitz J.I., Connolly S.J., Patel I., et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010, 104(3):633-641.
35. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
36. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365:699-708.
37. Kearon C., Akl E.A., Comerota A.J., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141(Suppl 2):e419S-e494S.
38. Kaatz S., Kouides P.A., Garcia D.A., et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012, 87:S141-S145.
39. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124(14):1573-1579.
40. Garcia D., Libby E., Crowther M.A. The new oral anticoagulants. Blood 2010, 115:15-20.